A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly s.c. Administered GL0034 in Adults with Type 2 Diabetes Mellitus Inadequately controlled on Metformin Or Diet and Exercise - SP-GL0034-02
Latest Information Update: 15 Sep 2025
At a glance
- Drugs Utreglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Sun Pharmaceutical Industries
Most Recent Events
- 15 Sep 2025 New trial record